Efficacy of APG777 in Patients with Atopic Dermatitis and Evidence of Type 2 Inflammatory Comorbidities: Results from the Phase 2 APEX Study

Authors

• Linda F. Stein Gold, Henry Ford HealthFollow
• Jonathan Silverberg
• Andrew Blauvelt
• Melinda Gooderham
• Kenji Kabashima
• Catherine Maari
• Susanna Wen
• Olivia Choi
• Christine Wang
• Li Xie
• Joshua Cirulli
• Kristine Nograles
• Amol Kamboj
• Emma Guttman-Yassky

Recommended Citation

Stein Gold LF, Silverberg J, Blauvelt A, Gooderham M, Kabashima K, Maari C, Wen S, Choi O, Wang C, Xie L, Cirulli J, Nograles K, Kamboj A, Guttman-Yassky E. Efficacy of APG777 in Patients with Atopic Dermatitis and Evidence of Type 2 Inflammatory Comorbidities: Results from the Phase 2 APEX Study. J Allergy Clin Immunol 2026; 157(2):AB424.

Document Type

Conference Proceeding

Publication Date

2-10-2026

Publication Title

J Allergy Clin Immunol

Keywords

immunoglobulin E, interleukin 13, placebo, adult, aged, asthma, atopic dermatitis, comorbidity, conference abstract, controlled study, drug therapy, Eczema Area and Severity Index, female, human, inflammation, major clinical study, male, phase 2 clinical trial, randomized controlled trial

Abstract

Rationale: APG777 is the first half-life-extended anti-IL-13 antibody to be evaluated in atopic dermatitis (AD). As AD is often associated with comorbid type 2 inflammatory diseases, we evaluated APG777 in patients with AD with and without evidence of asthma and sinonasal conditions in the phase 2 APEX Part A study (NCT06395948). Methods: Adults (N=123) with moderate-to-severe AD were randomized 2:1 to APG777 (720mg Day 1, Week 2; 360mg Weeks 4, 12) or placebo. For this post-hoc, as-observed analysis, treatment comparisons in participants with and without evidence of type 2 comorbidities at baseline were assessed by the percentage achieving 75% improvement in the Eczema Area and Severity Index (EASI-75) at Week 16. Results: Treatment with APG777 led to an overall EASI-75 response rate of 74.7% (n=56/75) at Week 16 (vs. 26.3% [n=10/38] placebo; p<0.001). Among participants with a history of asthma and/or sinonasal conditions, 71.1% (n=27/38) of APG777-treated participants achieved EASI-75 at Week 16 (vs. 36.8% [n=7/19] placebo). Similarly, among participants without a history of asthma and sinonasal conditions, more APG777- vs. placebo-treated participants achieved EASI-75 (78.4% [n=29/37] vs. 15.8% [3/19]). EASI-75 response rates were also greater with APG777 vs. placebo for subgroups with baseline BEC≥300 cells/μL (71.1% vs. 19.0%), BEC<300 cells/μL (78.4% vs. 35.3%), IgE≥100 IU/mL (76.4% vs. 32.0%), and IgE<100 IU/mL (70.0% vs. 15.4%). No new safety signals were detected in patients with or without asthma and sinonasal conditions. Conclusions: Treatment with APG777 was well-tolerated and provided clinically meaningful improvements in AD signs and symptoms, regardless of coexisting type 2 inflammatory conditions.

Volume

157

Issue

2

First Page

AB424